

1614 160



DOCKET NO.: PSU-0016

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Miller, et al.

Serial No.: 09/623,568

Group Art Unit: 1614

Filing Date: August 31, 2000

Examiner: Not Assigned Yet

For: USE OF A HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR TREATMENT AND DIAGNOSIS OF CANCER

RECEIVED JUN 15 2005 TECH CENTER 1600/2900

DATE OF DEPOSIT: 6/14/05

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Janet E. Reed
TYPED NAME: Janet E. Reed
REGISTRATION NO.: 36,252

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION FOR WITHDRAWAL OF ABANDONMENT

During a recent review and status check of the above-identified application, Applicants learned that the above-identified application became abandoned for failure to respond to the Notice to File Missing Requirements dated July 11, 2001.

Based on the evidence submitted herewith, Applicants petition that the abandonment asserted by the Office be withdrawn as there is no abandonment in fact.

Submitted herewith is:

- A copy of the postcard identifying the papers filed and showing the U.S. PTO receipt stamp dated **November 13, 2001**.
- A copy of the complete response timely filed.
- A copy of Express Mail Label No. EL899364589 which is the number identified on the first page of the previously filed response showing a written "date in" of November 13, 2001.

- Applicants authorize the Commissioner to charge Deposit Account No. 23-3050 in the amount of the petition fee. However, as no defect exists in applicant's previous submission, an immediate refund of the petition fee is requested.

- The Commissioner is hereby authorized to charge payment of the above fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in duplicate.

Date:

6/10/2005



Janet E. Reed

Registration No. 36,252

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



RECEIVED
JUN 15 2005
TECH CENTER 1600/2900

RECEIVED BY THE UNITED STATES
PATENT AND TRADEMARK OFFICE
Via Express Mail # EL 899364589 US

Paper: Transmittal Letter to PCT/DE/EO/US in duplicate; Change of Correspondence Address (1 sh.); Petition for Extension of Time (2 sh.); Transmittal Letter Submitting Sequence Listing (1 sh.); Statement to Support Filing and Submission (1 sh.); sequence listing in written form (8 sh.) and computer readable format (1 diskette); copy of Notification of Missing Requirements (2 sh.); Check for \$200.00.

Applicant(s): Barbara MILLER, et al.

Serial No.: 09/623,568
International Filing Date: 05 March 1999

Docket No.: PSU-0016
Date Sent: November 13, 2001 JER/vchicchi

RECEIVED BY THE UNITED STATES
PATENT AND TRADEMARK OFFICE
Via Express Mail # EL 899364589 US

Paper: Transmittal Letter to PCT/DE/EO/US in duplicate; Change of Correspondence Address (1 sh.); Petition for Extension of Time (2 sh.); Transmittal Letter Submitting Sequence Listing (1 sh.); Statement to Support Filing and Submission (1 sh.); sequence listing in written form (8 sh.) and computer readable format (1 diskette); copy of Notification of Missing Requirements (2 sh.); Check for \$200.00.

Applicant(s): Barbara MILLER, et al.

Serial No.: 09/623,568
International Filing Date: 05 March 1999

Docket No.: PSU-0016
Date Sent: November 13, 2001 JER/vchicchi

JCO7 Rec'd PCT/PTO 13 NOV 2001

NEXT AVAILABLE COPY



EL 899364589 US

RECEIVED JUN 15 2005 TECH CENTER 1800/2800

EXPRESS MAIL POST OFFICE TO ADDRESSEE
UNITED STATES POSTAL SERVICE®

ORIGIN (POSTAL USE ONLY)		
PO ZIP Code	Day of Delivery	Flat Rate Envelope
Date In	Next Second	Postage
Time In	12 Noon 3 PM	Return Receipt Fee
Weight	Military Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery	Acceptance Clerk Initials	Total Postage & Fees

DELIVERY (POSTAL USE ONLY)		
Delivery Attempt	Time	Employee Signature
Mo. Day	AM PM	
Delivery Attempt	Time	Employee Signature
Mo. Day	AM PM	
Delivery Date	Time	Employee Signature
Mo. Day	AM PM	

WAIVER OF SIGNATURE (Domestic Only): Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY Weekend Holiday

Mailing Label Label 11-F August 2000

CUSTOMER USE ONLY
METHOD OF PAYMENT: Express Mail Corporate Acct. No. **X191468**

FROM: (PLEASE PRINT) **WOODCOCK WASHBURN KURTZ MACKIE**
LIBERTY PL FL 40 PHILADELPHIA PA 19103-7301
PSU 0016 (V Chicchi)

215 568 3100

Federal Agency Acct. No. or Postal Service Acct. No.

TO: (PLEASE PRINT) **ASSISTANT COMMISSIONER FOR PATENTS**
ATTN: BOX PCT/RO/US WASHINGTON DC 20231-0001

F02 T12


26/ 200

PRESS HARD. You are making 3 copies. **FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com**

EXPRESS MAIL POST OFFICE TO ADDRESSEE
UNITED STATES POSTAL SERVICE®



EL 899364589 US



SEE REVERSE SIDE FOR SERVICE GUARANTEES AND LIMITS ON INSURANCE COVERAGE

ORIGIN (POSTAL USE ONLY)		
PO ZIP Code	Day of Delivery	Flat Rate Envelope
Date In	Next Second	Postage
Time In	12 Noon 3 PM	Return Receipt Fee
Weight	Military Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery	Acceptance Clerk Initials	Total Postage & Fees

WAIVER OF SIGNATURE (Domestic Only): Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY Weekend Holiday

Customer Copy Label 11-F August 2000

CUSTOMER USE ONLY
METHOD OF PAYMENT: Express Mail Corporate Acct. No. **X191468**

FROM: (PLEASE PRINT) **WOODCOCK WASHBURN KURTZ MACKIE**
LIBERTY PL FL 40 PHILADELPHIA PA 19103-7301
PSU 0016 (V Chicchi)

215 568 3100

Federal Agency Acct. No. or Postal Service Acct. No.

TO: (PLEASE PRINT) **ASSISTANT COMMISSIONER FOR PATENTS**
ATTN: BOX PCT/RO/US WASHINGTON DC 20231-0001

F02 T12

26/

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com

BEST AVAILABLE COPY

OFFICE
JUN 13 2005

INTERNATIONAL APPLICATION NO.
PCT/US99/04996

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL FILING DATE
05 March 1999

ATTORNEY DOCKET NUMBER
PSU-0016

U.S. APPLICATION NO. (if known see 37 C.F.R. 1.5)
09/623,568

PRIORITY DATE CLAIMED
05 March 1998

TITLE OF INVENTION USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR TREATMENT AND DIAGNOSIS OF CANCER

APPLICANT(S) FOR DO/EO/US Barbara MILLER, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US)
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) 35 U.S.C. 371(c)(4).
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

RECEIVED
JUN 15 2005
TECH CENTER 1600/2900

- Items 11. to 16. below concern other document(s) or information included:
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 5.28 and 3.31 is included.
 13. A **FIRST** preliminary amendment.
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
 14. A substitute specification.
 15. A change of power of attorney and/or address letter.
 16. Other items or information:
 - Transmittal Letter submitting Sequence Listing.
 - Sequence Listing in computer readable form (1 diskette) and written form (8 sheets).
 - Statement to Support Filing and Submission.
 - Petition for Extension of Time.
 - Change of Correspondence Address.
 - Copy of Notification of Missing Requirements.

EXPRESS MAIL Mailing Label No. 899364589 US
Date of Deposit: 13 November 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

U.S. APPLICATION NO. (if known 37 C.F.R. 1.5)
09/623,568

INTERNATIONAL APPLICATION NO.
PCT/US99/04996

ATTORNEY DOCKET NUMBER
PSU-0016

17. The following fees are submitted:
Basic National Fee (37 CFR 1.492(a)(1) - (5)):
 Neither international preliminary examination fee (37 CFR 1.482)
 nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
 and International Search Report not prepared by the EPO or JPO.....\$1,040.00

International preliminary examination fee (37 CFR 1.482 not paid to USPTO
 but International Search Report has been prepared by the EPO or JPO.....\$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
 international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$740.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) but
 all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$710.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and
 all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00

CALCULATIONS PTO USE ONLY

ENTER APPROPRIATE BASIC FEE AMOUNT = \$

Surcharge of \$130.00 for furnishing the oath or declaration later than _ 20 _ 30 months from
the earliest claimed priority date (37 CFR 1.492(e)). \$

Claims	Number Filed	Number Extra	Rate	
Total claims	- 20 =		X \$18.00	\$
Independent Claims	- 3 =		x \$84.00	\$
Multiple dependent claims(s) (if applicable)			+ \$280.00	\$

TOTAL OF ABOVE CALCULATIONS = \$

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are
reduced by 1/2. \$

SUBTOTAL = \$

Processing fee of \$130.00 for furnishing the English translation later than the _ 20 _ 30 months
from the earliest claimed priority date (37 CFR 1.492(f)). + \$

TOTAL NATIONAL FEE = \$

Fee for Petition for Extension of Time (Small Entity) + \$200.00

TOTAL FEES ENCLOSED = \$200.00


Amount to be: refunded	\$
charged	\$


- a. A check in the amount of \$ 200.00 to cover the above fee is enclosed.
- b. Please charge my Deposit Account No. 23-3050 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-3050. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Janet E. Reed
Woodcock Washburn LLP
One Liberty Place - 46th Floor


 SIGNATURE
 Janet E. Reed
 NAME



RECEIVED
JUL 16 2001



Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO. 09/623568	FIRST NAMED APPLICANT MILLER	ATTY. DOCKET NO. 98-1895
INTERNATIONAL APPLICATION NO. PCT/US99/04996		
I.A. FILING DATE 05 MAR 99	PRIORITY DATE 05 MAR 98	

THE PENNSYLVANIA STATE UNIVERSITY
113 TECHNOLOGY CENTER
UNIVERSITY PARK, PA 16802

DATE MAILED: 11 JUL 2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

RECEIVED

JUN 16 2005

TECH CENTER 1600/2900

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494) an Elected Office (37 CFR 1.495):
- | | |
|---|---|
| <input checked="" type="checkbox"/> U.S. Basic National Fee. | <input type="checkbox"/> Indication of Small Entity Status. |
| <input checked="" type="checkbox"/> Copy of the international application. | <input type="checkbox"/> Translation of the international application into English. |
| <input checked="" type="checkbox"/> Oath or Declaration of inventors(s). | <input type="checkbox"/> Translation of Article 19 amendments into English. |
| <input type="checkbox"/> Copy of Article 19 amendments. | <input type="checkbox"/> Other: |
| <input checked="" type="checkbox"/> Priority Document. | |
| <input type="checkbox"/> The International Preliminary Examination Report in English and its Annexes, if any. | |
| <input type="checkbox"/> Translation of Annexes to the International Preliminary Examination Report into English. | |
2. Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.
- | | |
|---|---|
| <input type="checkbox"/> U.S. Basic National Fee. | <input type="checkbox"/> Copy of the international application. |
|---|---|
3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
 - The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
 - b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
 - c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
 - The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
 - d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).
4. Additional claim fees of \$ _____ as a large entity small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.
5. Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).


6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

Enclosed: PCT/DO/EO/917 Notice of Defective Translation
 PTO-875 PCT/DO/EO/920

Pat. Booker, Paralegal
 Telephone: (703) 306-3738



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO. 09/623568	FIRST NAMED APPLICANT MILLER	ATTY. DOCKET NO. 98-1895
THE PENNSYLVANIA STATE UNIVERSITY 113 TECHNOLOGY CENTER UNIVERSITY PARK, PA 16802		INTERNATIONAL APPLICATION NO. PCT/US99/04896
		I.A. FILING DATE 05 MAR 99
		PRIORITY DATE 05 MAR 98
DATE MAILED: 11 JUL 2001		

TECH CENTER 1600/2900

JUN 16 2005

RECEIVED

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- Other: _____

APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

Pat Booker, Paralegal

Telephone: (703) 305-3738

FORM PCT/DO/EO/920 (March 2001)

RECEIVED

JUN 15 2005

DOCKET NO.: PSU-0016

TECH CENTER 1600/2900

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Barbara MILLER, et al.

Serial No.: 09/623,568

Group Art Unit: not yet known

Intl. Appln. No.: PCT/US99/04996

Int. Filing Date: 05 March 1999

Examiner: submitted herewith

For: USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR TREATMENT AND DIAGNOSIS OF CANCER

Assistant Commissioner for Patents
Washington DC 20231

CHANGE OF CORRESPONDENCE ADDRESS

Please change the Correspondence Address for the above-identified application to:

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103

I am the:

- Applicant
- Assignee of record of the entire interest. Statement under 37 CFR 3.73(b) is enclosed.
- Attorney or agent of record

Date: 11/13/01

Janet E. Reed
Registration No. 36,252

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

RECEIVED

JUN 15 2005

DOCKET NO.: PSU-0016

TECH CENTER 1600/2900

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Barbara MILLER, et al.

U.S. Serial No.: 09/623,568

Group Art Unit: not yet known

Intl. Application No.: PCT/US99/04996

Intl. Filing Date: 05 March 1999

Examiner: not yet assigned

For: USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR
TREATMENT AND DIAGNOSIS OF CANCER

Assistant Commissioner for Patents
Washington DC 20231

PETITION FOR EXTENSION OF TIME

Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Notification of Missing Requirements of **July 11, 2001** to and through **November 11, 2001** comprising an extension of the shortened statutory period of **two (2) month(s)**:

	SMALL ENTITY		NOT SMALL ENTITY	
	RATE	FEE	RATE	FEE
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME	\$55	\$	\$110	\$
<input checked="" type="checkbox"/> TWO MONTH EXTENSION OF TIME	\$200	\$200	\$400	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME	\$460	\$	\$920	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME	\$720	\$	\$1440	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME	\$980	\$	\$1960	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID	minus	(\$)	minus	(\$)
TOTAL FEE DUE		\$200		


An extension for _____ has already been secured and the fee paid therefore of \$____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$_____

A check in the amount of \$ 200.00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Please charge my Deposit Account No. 23-3050 in the amount of \$____.
This sheet is attached in duplicate.

Date: 11/13/01



 Janet E. Reed
 Registration No. 36,252

Woodcock Washburn LLP
 One Liberty Place - 46th Floor
 Philadelphia PA 19103
 Telephone: (215) 568-3100
 Facsimile: (215) 568-3439


RECEIVED

JUN 15 2005.

TECH CENTER 1600/2900

PSU-0016

IN THE UNITED STATES RECEIVING OFFICE
Before the United States Receiving Office
for the Patent Cooperation Treaty



IPC application of:

Barbara MILLER, et al.

U.S. Serial No.: 09/623,568

International Application No.: PCT/US99/04996

International Filing Date: 05 March 1999

For: USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR
TREATMENT AND DIAGNOSIS OF CANCER


Assistant Commissioner for Patents
BOX PCT DO/EO/US
Washington, DC 20231

TRANSMITTAL LETTER SUBMITTING SEQUENCE LISTING

Applicant submits herewith the Sequence Listing in written (8 sheets) and computer readable form (1 diskette), the contents of which are the same.

The enclosed Sequence Listing does not go beyond the disclosure in the international application as filed.

Respectfully submitted,


Janet E. Reed
Registration No. 36,252

/vc

Enc.: 1 Diskette ; 8 sheets sequence listing
Date: 13 November 2001
WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100

DOCKET NO.: PSU-0016

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 15 2005

In Re Application of:

Barbara MILLER, et al.

TECH CENTER 1600/2900

U.S. Serial No.: 09/623,568

Intl. Appln. No.: PCT/US99/04996

Group Art Unit: not yet known

Int. Filing Date: 05 March 1999

Examiner: not yet assigned

For: USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR TREATMENT AND DIAGNOSIS OF CANCER

Assistant Commissioner for Patents
Washington DC 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Date: 11/13/01

Janet E. Reed
Registration No. 36,252

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Tel: (215) 568-2100



RECEIVED

JUN 15 2005

TECH CENTER 1600/2900

SEQUENCE LISTING

<110> Miller, Barbara
Osmani, Stephen
Clawson, Gary
Zhang, Min-Ying
Norris, James

<120> Use of Human Homolog Of A Nuclear Migration Gene For Treatment And Diagnosis Of Cancer

<130> PSU-0016

<140> 09/623,568

<141> 2001-03-23

<150> 60/076,885

<151> 1998-03-05

<150> PCT US99/04996

<151> 1999-03-05

<160> 16

<170> PatentIn version 3.1

<210> 1

<211> 14

<212> PRT

<213> artificial Sequence

<220>

<223> Peptide

<400> 1

Gly Cys Met Val Glu Lys Met Met Tyr Asp Gln Arg Gln Lys
1 5 10

<210> 2

<211> 15

<212> PRT

<213> artificial Sequence

<220>

<223> Peptide

<400> 2

Asn Gly Ser Leu Asp Ser Pro Gly Lys Gln Asp Thr Glu Glu Asp
1 5 10 15

<210> 3

<211> 24

<212> DNA

<213> artificial Sequence

<220>

<223> Oligonucleotide

<400> 3

ttctgttcgt ctgaagttgg cagc

24

<210> 4

<211> 24

<212> DNA

<213> artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 4
 caatgaagtg aagtgagg agag 24

<210> 5
 <211> 38
 <212> DNA
 <213> artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 5
 aaggtaccaa gatggactcc ccaggaagc aggatact 38

<210> 6
 <211> 32
 <212> DNA
 <213> artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 6
 aaggtaccaa gaaagttggg tggttgcagc tc 32

<210> 7
 <211> 20
 <212> DNA
 <213> artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 7
 gaaagtcgga ggttcgaaga 20

<210> 8
 <211> 20
 <212> DNA
 <213> artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 8
 accaactaag aacggccatg 20

<210> 9
 <211> 24
 <212> DNA
 <213> artificial Sequence
 <220>
 <223> Oligonucleotide
 <400> 9
 agcaacatgc cgtcgaaccg ctcc 24

<210> 10
<211> 24
<212> DNA
<213> artificial Sequence

<220>
<223> Oligonucleotide

<400> 10
ggagcggttc gacggcatgt tgct 24

<210> 11
<211> 1281
<212> DNA
<213> Homo sapiens

<400> 11
ctagagtgc gagctccggg acgtggatcg gagccggcgc gatgggcgga gagcaggagg 60
aggagcgggt cgacggcatg ttgctggcca tggctcagca gcacgagggc ggcgtgcagg 120
agcttgtgaa caccttcttc agcttccttc gacgcaaac agactttttc attggaggag 180
aagaagggat ggcagagaag cttatcacac agactttcag ccaccacaat cagctggcac 240
agaagaccgg gcgggagaag agagcccggc aggaggccga gcggcgggag aaggcggagc 300
gggcggccag actggccaag gaagccaagt cagagacctc agggccccag atcaaggagc 360
taactgatga agaggcagag aggctgcagc tagagattga ccagaaaaag gatgcagaga 420
atcatgaggc ccagctcaag aacggcagcc ttgactcccc aggggaagcag gatactgagg 480
aagatgagga ggaagatgag aaggacaaag gaaaactgaa gcccaaccta ggcaacgggg 540
cagacctgcc caattaccgc tggaccaga cctgtcggga gctggacctg gcggtccctt 600
tctgtgtgaa cttccggctg aaaggggaag acatggtggt ggacatccag cggcggcacc 660
tccgggtggg gctcaagggg cagccagcga tcattgatgg ggagctctac aatgaagtga 720
aggtggagga gagctcgtgg ctcatgagg acggcaaggt ggtgactgtg catctggaga 780
agatcaataa gatggagtgg tggagccgct tgggtgccag tgaccctgag atcaacacca 840
agaagattaa ccctgagaat tccaagctgt cagacctgga cagtgagact cgcagcatgg 900
tggaaaagat gatgtatgac cagcgacaga agtccatggg gctgccaaact tcagacgaac 960
agaagaaaca ggagattctg aagaagtca tggatcaaca tccggagatg gatTTTTCCA 1020
aggctaaatt caactagccc ctgtTTTTTC ctccctgaac tcttggggct gagctgcaac 1080
caccctaaatt tctttccac tcttctctgg gacttgtggg cctcagggct tggggcaggc 1140
atgggactgg ccaggcaca caggtcccgg ggcacagga gaaaggctgg gtcttgggac 1200
cttgtcctcc ccagttggcc tactgttaca cattaaaacg atttgcccag ctcaaaaaaa 1260
aaaaaaaaa aaaaaaaaaa a 1281

<210> 12
<211> 331
<212> PRT
<213> Homo sapiens

<400> 12

Met Gly Gly Glu Gln Glu Glu Glu Arg Phe Asp Gly Met Leu Leu Ala
1 5 10 15

Met Ala Gln Gln His Glu Gly Gly Val Gln Glu Leu Val Asn Thr Phe
20 25 30

Phe Ser Phe Leu Arg Arg Lys Thr Asp Phe Phe Ile Gly Gly Glu Glu
35 40 45

Gly Met Ala Glu Lys Leu Ile Thr Gln Thr Phe Ser His His Asn Gln
50 55 60

Leu Ala Gln Lys Thr Arg Arg Glu Lys Arg Ala Arg Gln Glu Ala Glu
65 70 75 80

Arg Arg Glu Lys Ala Glu Arg Ala Ala Arg Leu Ala Lys Glu Ala Lys
85 90 95

Ser Glu Thr Ser Gly Pro Gln Ile Lys Glu Leu Thr Asp Glu Glu Ala
100 105 110

Glu Arg Leu Gln Leu Glu Ile Asp Gln Lys Lys Asp Ala Glu Asn His
115 120 125

Glu Ala Gln Leu Lys Asn Gly Ser Leu Asp Ser Pro Gly Lys Gln Asp
130 135 140

Thr Glu Glu Asp Glu Glu Glu Asp Glu Lys Asp Lys Gly Lys Leu Lys
145 150 155 160

Pro Asn Leu Gly Asn Gly Ala Asp Leu Pro Asn Tyr Arg Trp Thr Gln
165 170 175

Thr Leu Ser Glu Leu Asp Leu Ala Val Pro Phe Cys Val Asn Phe Arg
180 185 190

Leu Lys Gly Lys Asp Val Val Val Asp Ile Gln Arg Arg His Leu Arg
195 200 205

Val Gly Leu Lys Gly Gln Pro Ala Ile Ile Asp Gly Glu Leu Tyr Asn
210 215 220

Glu Val Lys Val Glu Glu Ser Ser Trp Leu Ile Glu Asp Gly Lys Val
225 230 235 240

Val Thr Val His Leu Glu Lys Ile Asn Lys Met Glu Trp Trp Ser Arg
245 250 255

Leu Val Ser Ser Asp Pro Glu Ile Asn Thr Lys Lys Ile Asn Pro Glu
Page 4

260

265

270

Asn Ser Lys Leu Ser Asp Leu Asp Ser Glu Thr Glu Ser Met Val Glu
275 280 285

Lys Met Met Tyr Asp Gln Arg Gln Lys Ser Met Gly Leu Pro Thr Ser
290 295 300

Asp Glu Gln Lys Lys Gln Glu Ile Leu Lys Lys Phe Met Asp Gln His
305 310 315 320

Pro Glu Met Asp Phe Ser Lys Ala Lys Phe Asn
325 330

<210> 13
<211> 332
<212> PRT
<213> Rattus rattus

<400> 13

Met Gly Gly Glu Gln Glu Glu Arg Phe Asp Gly Met Leu Leu Ala
1 5 10 15

Met Ala Gln Gln His Glu Gly Gly Val Gln Glu Leu Val Asn Thr Phe
20 25 30

Phe Ser Phe Leu Arg Arg Lys Thr Asp Phe Phe Ile Gly Gly Glu Glu
35 40 45

Gly Met Ala Glu Lys Leu Ile Thr Gln Thr Phe Asn His His Asn Gln
50 55 60

Leu Ala Gln Lys Ala Arg Arg Glu Lys Arg Ala Arg Gln Leu Thr Glu
65 70 75 80

Arg Arg Glu Lys Ala Glu Arg Ala Ala Arg Leu Ala Lys Glu Ala Lys
85 90 95

Ala Glu Thr Pro Gly Pro Gln Ile Lys Glu Leu Thr Asp Leu Lys Ala
100 105 110

Glu Arg Leu Gln Leu Glu Ile Asp Gln Lys Lys Asp Ala Glu Asn His
115 120 125

Glu Val Gln Leu Lys Asn Gly Ser Leu Asp Ser Pro Gly Lys Gln Asp
130 135 140

Ala Leu Leu Glu Glu Asp Glu Glu Asp Glu Lys Asp Lys Gly Lys Leu
145 150 155 160

Lys Pro Asn Leu Gly Asn Gly Ala Asp Leu Pro Asn Tyr Arg Trp Thr
165 170 175

Gln Thr Leu Ser Phe Leu Asp Leu Ala Val Pro Phe Arg Val Ser Phe
180 185 190

Arg Leu Lys Gly Lys Gln Val Val Val Asp Ile Gln Arg Arg His Leu
195 200 205

Arg Val Gly Leu Lys Gly Gln Ala Pro Val Ile Asp Gly Glu Leu Tyr
210 215 220

Asn Glu Val Lys Val Glu Glu Ser Ser Trp Leu Ile Glu Asp Gly Lys
225 230 235 240

Val Val Thr Val His Leu Glu Lys Ile Asn Lys Met Glu Trp Trp Asn
245 250 255

Arg Leu Val Thr Ser Asp Pro Glu Ile Asn Thr Lys Lys Ile Asn Pro
260 265 270

Glu Asn Ser Lys Leu Ser Asp Leu Asp Ser Glu Thr Arg Ser Met Val
275 280 285

Glu Lys Met Met Tyr Asp Gln Arg Gln Lys Ser Met Gly Leu Pro Thr
290 295 300

Ser Asp Glu Gln Lys Lys Gln Glu Ile Leu Lys Lys Phe Met Asp Gln
305 310 315 320

His Pro Glu Met Asp Phe Ser Lys Ala Lys Phe Asn
325 330

<210> 14
<211> 202
<212> PRT
<213> Aspergillus nidulans

<400> 14

Met Ser Glu Gln Glu Pro Ser Ser Ala Asp Leu Ala Ala Arg Glu Ala
1 5 10 15

Glu Glu Lys Gln Arg Lys Ala Ala Glu Glu Ala Glu Gln Ala Thr Leu
20 25 30

Pro Tyr Lys Asn Thr Gln Thr Ile Arg Asp Val Asp Val Phe Thr Thr
35 40 45

Ile Pro Val Ser Ala Asn Leu Lys Gly Arg Asp Leu Asp Val Val Leu
50 55 60

Lys Lys Asp Ser Ile Lys Val Lys Val Lys Gly Glu Asn Gly Glu Val
65 70 75 80

Phe Ile Asp Gly Gln Phe Pro His Pro Ile Lys Pro Ser Glu Ser Ser
85 90 95

Trp Thr Leu Glu Thr Thr Ser Lys Pro Pro Phe Thr Gly Lys Glu Val
100 105 110

Ser Ile His Leu Asp Lys Val Asn Gln Met Glu Trp Trp Ala Met Val
115 120 125

Val Thr Thr Ala Pro Lys Ile Asp Val Ser Lys Ile Thr Phe Glu Asn
130 135 140

Ser Ser Leu Ser Asp Leu Asp Gly Glu Thr Arg Ala Met Val Glu Lys
145 150 155 160

Met Met Tyr Asp Gln Arg Gln Lys Glu Met Gly Ala Pro Thr Ser Asp
165 170 175

Glu Gln Arg Lys Met Asp Ile Leu Lys Lys Phe Gln Lys Glu His Pro
180 185 190

Glu Met Asp Phe Ser Asn Ala Lys Ile Gly
195 200

<210> 15
<211> 93
<212> PRT
<213> artificial Sequence

<220>
<223> Consensus Sequence

<400> 15

Ser Phe Asp Glu Lys Glu Ala Leu Pro Tyr Asn Thr Gln Thr Asp Val
1 5 10 15

Leu Lys Gly Asp Val Val Lys Ile Asp Gly Lys Glu Ser Ser Trp Glu
20 25 30

Gly Lys Val His Leu Lys Asn Met Glu Trp Trp Val Pro Ile Lys Ile
35 40 45

Pro Glu Asn Ser Leu Ser Asp Leu Asp Glu Thr Arg Met Tyr Glu Lys
50 55 60

Met Met Tyr Asp Gln Arg Gln Lys Met Gly Pro Thr Ser Asp Glu Gln
65 70 75 80

Lys Ile Leu Lys Lys Phe His Phe Glu Met Asp Phe Ser
85 90

<210> 16

<211> 12
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<222> (9)..(9)
<223> X=Any Amino Acid

<220>
<221> misc_feature
<222> (11)..(11)
<223> X=Any Amino Acid

<400> 16

Met Val Glu Lys Met Met Tyr Asp Xaa Arg Xaa Lys
1 5 10